
Mass. residents who take GLP-1 drugs for obesity tend to be white and affluent. But who needs them most?
Obesity, which afflicts about 40 percent of US adults, is more common among low-income residents and Black and Hispanic people than other ethnic and socio-economic groups. But the Globe analysis found that patients taking drugs such as Wegovy, Ozempic, …